Co-Diagnostics Expands Molecular Diagnostics Reach Across South Asia Through Joint Venture

Co-Diagnostics announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka. This expansion significantly increases the company's addressable market to an estimated $13.0 billion, representing a substantial growth opportunity for the molecular diagnostics provider. The move supports planned commercialization of the CoSara PCR Pro point-of-care platform and SARAGENE product line, subject to regulatory approvals, as the company builds regional distribution channels.

The expansion positions Co-Diagnostics for broader deployment of its molecular diagnostics solutions across a region with significant healthcare needs. The company's technologies are utilized for tests designed using the detection and analysis of nucleic acid molecules, which form the foundation of modern molecular diagnostics. This territorial expansion comes as the company continues to develop its proprietary technology for specific tests designed for its Co-Dx PCR at-home and point-of-care platform, though these remain subject to regulatory review and are not currently for sale.

Forward-looking statements in the announcement highlight that actual results may differ materially from expectations due to various factors beyond management's control. These include risks detailed in the company's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC, available through the company's investor relations website at https://co-dx.com/. The expansion represents a strategic move to increase market penetration in South Asia, where demand for advanced diagnostic solutions continues to grow alongside healthcare infrastructure development.

The agreement enables CoSara Diagnostics to establish commercial operations across the newly added territories, creating pathways for distribution of molecular diagnostic products. This development occurs within the broader context of increasing global demand for PCR-based testing solutions, particularly following widespread adoption during recent public health challenges. The company's approach focuses on building regional distribution channels that can support healthcare providers across diverse markets with varying regulatory requirements and healthcare system structures.

Molecular diagnostics represents a rapidly growing segment within the global healthcare market, with applications extending beyond infectious disease to include genetic marker identification. The expansion into additional South Asian markets aligns with broader industry trends toward decentralized testing and point-of-care solutions that can deliver rapid results outside traditional laboratory settings. As regulatory processes proceed in each new territory, the company will work to establish the necessary approvals for product commercialization while building the infrastructure required to support healthcare providers across the region.